How Does Norethindrone Work for Endometriosis?

Norethindrone acetate is one of the most widely prescribed progestins for managing endometriosis-related pain, and the evidence supports its effectiveness. In clinical studies, it consistently drives pain scores down to near zero over several months of continuous use, and it does so at a fraction of the cost of newer hormonal options. But the drug works differently for different people, and understanding why requires a closer look at how it interacts with endometrial tissue, what side effects to expect, and when it might not be enough.

How Norethindrone Works Against Endometriosis

Norethindrone acetate (often abbreviated NETA) is a synthetic progestin, meaning it mimics the hormone progesterone. In endometriosis, tissue resembling the uterine lining grows in places it shouldn’t, and that tissue responds to the hormonal shifts of the menstrual cycle by thickening, breaking down, and causing inflammation. NETA suppresses ovulation and thins endometrial tissue throughout the body, starving those misplaced lesions of the hormonal signals they need to grow.

What sets norethindrone apart from natural progesterone is its direct cellular activity. In lab studies, norethindrone significantly inhibited the growth of endometriotic stromal cells in a dose-dependent way and, at higher concentrations, triggered programmed cell death in those cells, something natural progesterone did not do.¹ In other words, norethindrone doesn’t just slow endometriotic tissue growth; it can actively push those cells toward dying off.

Norethindrone also dials down the inflammatory environment that makes endometriosis painful. When endometriotic cells were exposed to inflammatory signals in the lab, NETA suppressed the production of key inflammatory molecules and reduced cell proliferation.² This anti-inflammatory effect likely explains a good portion of its pain-relieving benefit beyond simple hormonal suppression.

NETA also has a unique pharmacological quirk: it partially converts into ethinyl estradiol in the body. This gives it mild estrogenic properties alongside its progestational and androgenic effects.³ That built-in estrogenic activity has practical consequences, both helpful and potentially problematic, which come up in several contexts below.

Pain Relief and Clinical Effectiveness

The clinical data on NETA for endometriosis pain is reassuringly consistent. In a randomized controlled trial comparing NETA with dienogest (a newer progestin widely used in Europe and parts of Asia), both drugs reduced dysmenorrhea scores from around 7 out of 10 at baseline to 0.00 at 12 months, with no significant difference between them. Chronic pelvic pain also improved substantially in both groups.⁴ That head-to-head result matters because dienogest is often presented as the more modern, more targeted option, yet NETA performed just as well for pain control.

Long-term data also looks encouraging. In a study tracking women with rectovaginal endometriosis, one of the more painful and difficult-to-treat forms, chronic pelvic pain and deep dyspareunia both dropped significantly during NETA treatment and stayed lower at both the one-year and five-year marks.⁵ About two-thirds of the women who completed five years of treatment said they were satisfied or very satisfied with the therapy, though it’s worth noting that roughly 40% of the original participants had dropped out by that point, many due to side effects.

For recurrent endometriomas (cysts that come back after surgery), NETA has shown the ability to shrink them over time. In one study, cyst size decreased significantly within as few as three months, with total regression taking an average of about ten months of continuous treatment.⁶ That’s a meaningful finding for anyone trying to avoid repeat surgery.

Typical Dosing and What to Expect

For endometriosis, NETA is usually prescribed at 5 mg daily, taken continuously without breaks. Some clinicians start at 2.5 mg and titrate up, while others go as high as 15 mg in certain cases. In a study of younger patients with surgically confirmed endometriosis, continuous NETA at 5 to 15 mg daily led to median pain scores dropping from 5 to 0 and bleeding scores from 2 to 0, regardless of disease stage.⁷

The goal of continuous dosing is to suppress menstruation entirely. When it works as intended, you stop having periods, which means the cyclical inflammation driving endometriosis pain is largely shut down. Most women achieve amenorrhea (no periods) within a few months, though irregular spotting or breakthrough bleeding is common early on.

A head-to-head comparison with dienogest found that NETA and dienogest were similarly effective for pain, but tolerability differed slightly. About 58% of NETA users reported no significant side effects, compared to 80% of dienogest users.⁸ Overall patient satisfaction was nearly identical between the two drugs, with about 71-72% of women in each group rating themselves as satisfied or very satisfied after six months. That side-effect gap is real but modest, and for many patients the cost difference tips the balance: NETA is available as a cheap generic, while dienogest can be considerably more expensive depending on the country and insurance coverage.

Side Effects and Tolerability

The side effects of NETA are roughly what you’d expect from a progestin, but a few specifics are worth flagging. In the study of younger patients, over half reported no side effects at all. The most commonly reported problem was weight gain, affecting about 16% of participants, with an average increase in BMI that worked out to a few pounds over a year.⁹ Other common complaints include bloating, fatigue, and abdominal cramps.¹⁰

Mood changes are a common worry with any hormonal therapy, but the data here is somewhat reassuring. In a randomized pilot trial comparing NETA to cabergoline for endometriosis, neither group showed a clinically meaningful level of depressive symptoms at any point during treatment, as measured by a standard depression inventory.¹¹ That said, the trial was small, and individual experiences vary widely. Mood effects are real for some people on progestins even when group averages look fine.

Breakthrough Bleeding

Irregular bleeding is one of the most frustrating side effects and a common reason women stop treatment. How much you bleed depends in part on how you started. In a study comparing different approaches, breakthrough bleeding was reported by about 68% of women who started NETA alone, versus only 14% of those who had been on a GnRH agonist first before switching to NETA.¹² The takeaway is that prior suppression of the endometrial lining with a GnRH agonist can dramatically reduce the bleeding you experience when transitioning to NETA alone. If breakthrough bleeding is a major concern, this sequential approach is worth discussing with your doctor.

Liver Safety at Higher Doses

One rare but serious concern involves liver health, specifically at higher doses. Case reports have documented hepatic adenomas (benign liver tumors) in adolescents and young women taking NETA at doses above 10 mg daily for endometriosis. The risk is thought to be related to the drug’s conversion to ethinyl estradiol, since estrogen exposure is a known driver of hepatic adenomas.¹³ For most women on the standard 5 mg dose, this is not a major concern, but anyone on higher doses should be aware of it, and NETA is generally not recommended in patients with known liver adenomas.

Use After Surgery

Surgery can remove visible endometriosis lesions, but recurrence is common. This is where NETA finds one of its most important roles: keeping disease from coming back. In a study of postoperative patients, continuous NETA significantly reduced both pain and bleeding compared to presurgical levels, and it worked across all stages of disease.¹⁴ The median pain score dropped from 5 to 0, which is a dramatic improvement for women who had been dealing with severe symptoms.

Prolonged postoperative hormonal therapy has been shown to be highly effective at preventing the return of endometriomas and recurrence of dysmenorrhea. The general consensus among specialists is that after excision surgery, some form of hormonal suppression should be strongly considered, and NETA is one of the most accessible options for that purpose.

NETA as Add-Back Therapy with GnRH Agonists

GnRH agonists like leuprolide essentially put the body into a temporary, reversible menopause-like state. That’s effective against endometriosis but creates serious side effects: hot flashes, vaginal dryness, and, critically, bone loss. Add-back therapy counteracts those problems by giving back small amounts of hormone while preserving the therapeutic effect.

NETA is particularly well-suited for this role because of its mixed hormonal profile. Its partial conversion to estrogen means it can serve as add-back therapy on its own, without needing a separate estrogen supplement.¹⁵ In practice, the standard add-back regimen uses 5 mg of NETA daily alongside a GnRH agonist. Clinical trials have tested this both alone and combined with conjugated estrogens at different doses.¹⁶

The bone-protective benefit of this combination is backed by direct measurement. In a prospective randomized trial, women who received NETA alongside a GnRH agonist had significantly less bone mineral density loss at the lumbar spine than those on the agonist alone, and the loss reversed more completely after treatment ended.¹⁷ For anyone who needs extended GnRH agonist therapy, this add-back approach makes long-term treatment feasible.

NETA in Newer Combination Therapies

The latest class of hormonal treatments for endometriosis uses oral GnRH antagonists instead of the injectable agonists that have been around for decades. Relugolix combination therapy, for example, pairs a GnRH antagonist with 1 mg of estradiol and 0.5 mg of norethindrone acetate in a single daily pill. Adding norethindrone and estradiol to the antagonist allows treatment to be extended to at least 24 weeks while maintaining pain relief and improving the side-effect profile compared to the antagonist alone.¹⁸ In these newer formulations, NETA serves both as endometrial protection (preventing the estrogen component from stimulating endometrial growth) and as a contributor to the overall anti-endometriotic effect.

Why It Doesn’t Work for Everyone

One of the more frustrating aspects of endometriosis treatment is that progestins, including NETA, simply do not provide adequate relief for a subset of patients. The concept researchers use to explain this is progesterone resistance: the endometriotic tissue stops responding normally to progesterone and its synthetic analogs.

The causes are layered. Chronic inflammation within endometriotic lesions can induce a state where progesterone receptors stop functioning properly, and progesterone is itself supposed to be anti-inflammatory, so this creates a vicious cycle.¹⁹ At the molecular level, the picture includes abnormal signaling, epigenetic changes to progesterone receptor genes, and environmental toxin exposure. One specific receptor subtype (PR-B) is frequently silenced in endometriotic tissue through a process called promoter hypermethylation, and exposure to certain environmental pollutants like dioxin can worsen this effect.²⁰

There are also genetic components. Polymorphisms in progesterone receptor genes, altered expression of small regulatory RNA molecules, and other epigenetic modifications all contribute to variability in how individuals respond to progestin therapy.²¹ None of these factors are routinely tested in clinical practice, which means that right now, discovering you’re resistant to progestins is largely a matter of trial and error. You try the drug, and if it doesn’t bring adequate relief after a reasonable period, your doctor moves on to other options.

Effects on Cholesterol and Cardiovascular Markers

Because NETA has both progestational and androgenic properties, its metabolic effects are worth understanding, especially for long-term users. A meta-analysis of 32 randomized trials examined what happens to lipid levels when estradiol is combined with norethindrone acetate. Total cholesterol and LDL (“bad”) cholesterol both dropped, which sounds good. But HDL (“good”) cholesterol also decreased, and this decline correlated with longer treatment duration.²² The net cardiovascular significance of these shifts is not straightforward because both LDL and HDL move in the same direction. In an animal study, the ratio of HDL to LDL remained essentially unchanged during high-dose norethindrone treatment, suggesting the relative balance wasn’t thrown off even as absolute levels shifted.²³

For most women using NETA at standard endometriosis doses, these lipid changes are unlikely to be clinically worrisome in the short or medium term. But for those on long-term therapy, especially women with pre-existing cardiovascular risk factors, periodic lipid monitoring is reasonable. The evidence here is largely from combined estrogen-progestin formulations rather than NETA alone, so the direct applicability to standalone NETA therapy at 5 mg for endometriosis involves some extrapolation.

Fertility After Stopping NETA

A common question for anyone with endometriosis is whether treatment will affect future fertility. NETA is not a permanent contraceptive; its effects on ovulation and the endometrium are reversible. Once you stop taking it, menstrual cycles typically resume within a few months, and fertility returns to whatever your baseline was. The drug itself does not appear to impair ovarian reserve or cause lasting reproductive harm.

The more complicated issue is that endometriosis itself is a leading cause of subfertility, and stopping hormonal suppression means the disease can resume its progression. Some clinicians use NETA specifically to preserve ovarian function and prevent endometrioma growth between surgical treatments, buying time until a patient is ready to conceive. The evidence that it can shrink recurrent endometriomas on its own supports this strategy.²⁴ But there is no strong evidence that taking NETA before trying to conceive improves your chances of pregnancy compared to other approaches. The calculus is really about symptom management and disease containment until you’re ready.

How NETA Compares to Other Progestins

The progestin landscape for endometriosis includes dienogest, medroxyprogesterone acetate, and various levonorgestrel-releasing devices. Each has its own pharmacological profile, and comparing them matters because switching between them is common when the first choice doesn’t work out.

Dienogest tends to get the most attention as a comparator. As the head-to-head trial data shows, the two drugs perform similarly for pain, with dienogest having a slight edge in tolerability. Lab studies suggest they share anti-inflammatory mechanisms: both suppressed inflammatory signals from endometriotic cells, though they differed in some secondary measures.²⁵ Where NETA has a clear advantage is cost and availability. It has been off-patent for decades, making it accessible in settings where dienogest is either unavailable or prohibitively expensive.

NETA’s unique estrogenic conversion also distinguishes it. Dienogest lacks this property, which means dienogest users are more likely to experience hypoestrogenic symptoms (hot flashes, vaginal dryness) than NETA users, though they’re also less likely to have estrogen-driven side effects. For add-back therapy alongside GnRH agonists, NETA’s built-in estrogenic activity is a genuine advantage, as it can serve double duty where dienogest cannot.

Adolescent and Young Adult Considerations

Endometriosis often begins during the teenage years, and early treatment can make a significant difference in quality of life. NETA has been studied specifically in this younger population. In the postoperative study of patients with a median age just under 19 years, the response was strong across all disease stages, with significant reductions in both pain and abnormal bleeding.²⁶

The main concern specific to younger patients is the potential effect on bone mineral density during a period when the skeleton is still building peak bone mass. Since NETA suppresses estrogen production to some degree (though less than GnRH agonists), prolonged use in adolescents warrants monitoring. The hepatic adenoma risk at doses above 10 mg per day is also particularly relevant here, since some younger patients are prescribed higher doses when standard regimens fail.²⁷ The general clinical approach is to use the lowest effective dose and to keep a close watch on liver imaging if higher doses become necessary.